Therefore, this method has been replaced by the FIT-Hb, which can detect and quantify faecal Hb and presents many advantages when compared to gFOBT, such as higher sensitivity for CRC and advanced adenomas; it only requires one stool sample and is more cost-effective [9,11,12]. The gene discussed is GSTM1; the disease is adenoma.